CN116211803B - 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR) - Google Patents

抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR) Download PDF

Info

Publication number
CN116211803B
CN116211803B CN202310263334.7A CN202310263334A CN116211803B CN 116211803 B CN116211803 B CN 116211803B CN 202310263334 A CN202310263334 A CN 202310263334A CN 116211803 B CN116211803 B CN 116211803B
Authority
CN
China
Prior art keywords
compound
liposome
atr
liposomes
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310263334.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN116211803A (zh
Inventor
D·C·德拉蒙德
B·耿
D·B·科波汀
S·K·蒂普帕拉朱
A·克什卡耶弗
O·阿尔坎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceutical Treatment Co.
Original Assignee
Celet Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celet Pharmaceuticals filed Critical Celet Pharmaceuticals
Priority to CN202310263334.7A priority Critical patent/CN116211803B/zh
Publication of CN116211803A publication Critical patent/CN116211803A/zh
Application granted granted Critical
Publication of CN116211803B publication Critical patent/CN116211803B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202310263334.7A 2016-01-11 2017-01-11 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR) Active CN116211803B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310263334.7A CN116211803B (zh) 2016-01-11 2017-01-11 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662277262P 2016-01-11 2016-01-11
US62/277,262 2016-01-11
US201662420258P 2016-11-10 2016-11-10
US62/420,258 2016-11-10
US201762444172P 2017-01-09 2017-01-09
US62/444,172 2017-01-09
PCT/US2017/012939 WO2017123588A1 (en) 2016-01-11 2017-01-11 Inhibiting ataxia telangiectasia and rad3-related protein (atr)
CN201780011422.0A CN108697811B (zh) 2016-01-11 2017-01-11 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR)
CN202310263334.7A CN116211803B (zh) 2016-01-11 2017-01-11 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780011422.0A Division CN108697811B (zh) 2016-01-11 2017-01-11 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR)

Publications (2)

Publication Number Publication Date
CN116211803A CN116211803A (zh) 2023-06-06
CN116211803B true CN116211803B (zh) 2024-10-11

Family

ID=59311885

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310263334.7A Active CN116211803B (zh) 2016-01-11 2017-01-11 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR)
CN201780011422.0A Active CN108697811B (zh) 2016-01-11 2017-01-11 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780011422.0A Active CN108697811B (zh) 2016-01-11 2017-01-11 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR)

Country Status (17)

Country Link
US (5) US10570119B2 (cg-RX-API-DMAC7.html)
EP (3) EP3936153B1 (cg-RX-API-DMAC7.html)
JP (4) JP6918829B2 (cg-RX-API-DMAC7.html)
KR (2) KR102461219B1 (cg-RX-API-DMAC7.html)
CN (2) CN116211803B (cg-RX-API-DMAC7.html)
AU (3) AU2017207299B2 (cg-RX-API-DMAC7.html)
DK (2) DK3402532T3 (cg-RX-API-DMAC7.html)
ES (2) ES2997263T3 (cg-RX-API-DMAC7.html)
FI (1) FI3936153T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241512T1 (cg-RX-API-DMAC7.html)
IL (2) IL260487B2 (cg-RX-API-DMAC7.html)
MA (1) MA43870A (cg-RX-API-DMAC7.html)
MX (1) MX2018008507A (cg-RX-API-DMAC7.html)
PL (1) PL3402532T3 (cg-RX-API-DMAC7.html)
PT (1) PT3936153T (cg-RX-API-DMAC7.html)
SI (1) SI3936153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017123588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
TWI755629B (zh) * 2018-09-13 2022-02-21 台灣微脂體股份有限公司 含鎮靜藥物之緩釋藥物組合物及其用途
EP3866764A4 (en) * 2018-10-17 2022-07-13 Taiwan Liposome Company, Ltd. DELAYED RELEASE PHARMACEUTICAL COMPOSITIONS WITH AN IMMUNOMODULATING AGENT AND USES THEREOF
US20230190752A1 (en) * 2020-05-07 2023-06-22 Washington University Compositions and methods for predicting therapeutic outcome
AU2021292747A1 (en) 2020-06-18 2023-02-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
EP4210692A4 (en) * 2020-09-14 2024-10-02 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel
AU2021360636A1 (en) 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
WO2025019346A2 (en) * 2023-07-14 2025-01-23 Celator Pharmaceuticals, Inc. Methods of use of a liposomal composition comprising an atr inhibitor
WO2025019344A2 (en) * 2023-07-14 2025-01-23 Jazz Pharmaceuticals, Inc. Combinations comprising an atr inhibitor and a parp inhibitor and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999632B2 (en) * 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990610A (en) 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DE602004015429D1 (de) 2003-03-11 2008-09-11 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
GB0411401D0 (en) 2004-05-21 2004-06-23 Tissuomics Ltd Penetrating radiation measurements
EP1778648A2 (en) 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
EP2153820A4 (en) 2007-05-14 2013-12-25 Konica Minolta Holdings Inc LIPOSOM AND METHOD FOR THE PRODUCTION OF LIPOSOMY
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
JP5951994B2 (ja) 2008-12-19 2016-07-13 イマージョン コーポレーションImmersion Corporation 対話型ペインティングゲーム及び関連するコントローラ
TW201028410A (en) * 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
BR112012005343A2 (pt) 2009-09-10 2016-03-22 Novartis Ag sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な化合物
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP2013529643A (ja) 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
CN102485213A (zh) * 2010-12-01 2012-06-06 沈阳药科大学 伊立替康脂质体及其制备方法
CN102485212B (zh) * 2010-12-01 2014-04-09 沈阳药科大学 苹果酸舒尼替尼脂质体及其制备方法
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (cg-RX-API-DMAC7.html) * 2011-09-30 2015-08-21 Vertex Pharma
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) * 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
US8912198B2 (en) * 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999632B2 (en) * 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents;Jean-Damien Charrier等;Journal of Medicinal Chemistry;第54卷(第7期);摘要,第2325页表4,第2324页左栏第1段 *

Also Published As

Publication number Publication date
IL313681B1 (en) 2026-08-01
AU2023282309B2 (en) 2025-09-18
JP7439023B2 (ja) 2024-02-27
IL260487B2 (en) 2024-11-01
JP2021176879A (ja) 2021-11-11
CN108697811A (zh) 2018-10-23
US11787781B2 (en) 2023-10-17
US11028076B2 (en) 2021-06-08
ES2997263T3 (en) 2025-02-14
US20190135789A1 (en) 2019-05-09
EP4438127A2 (en) 2024-10-02
CN108697811B (zh) 2023-04-07
JP2024023349A (ja) 2024-02-21
KR20180096787A (ko) 2018-08-29
JP2019505584A (ja) 2019-02-28
EP3936153A1 (en) 2022-01-12
IL260487B1 (en) 2024-07-01
EP3936153B1 (en) 2024-08-21
JP2026053650A (ja) 2026-03-25
PL3402532T3 (pl) 2022-08-22
EP4438127A3 (en) 2024-12-25
SI3936153T1 (sl) 2025-03-31
CN116211803A (zh) 2023-06-06
HRP20241512T1 (hr) 2025-01-03
PT3936153T (pt) 2024-11-25
JP6918829B2 (ja) 2021-08-11
MA43870A (fr) 2021-05-26
DK3402532T3 (da) 2022-07-11
FI3936153T3 (fi) 2024-11-21
KR20230002511A (ko) 2023-01-05
MX2018008507A (es) 2019-07-04
WO2017123588A1 (en) 2017-07-20
US20210300905A1 (en) 2021-09-30
ES2921008T3 (es) 2022-08-16
AU2025279601A1 (en) 2026-01-15
IL313681A (en) 2024-08-01
DK3936153T3 (da) 2024-11-25
AU2023282309A1 (en) 2024-01-18
EP3402532A4 (en) 2019-09-11
AU2017207299B2 (en) 2023-09-21
US10570119B2 (en) 2020-02-25
KR102461219B1 (ko) 2022-10-31
EP3402532B1 (en) 2022-04-13
AU2017207299A1 (en) 2018-08-02
US20200399247A1 (en) 2020-12-24
IL260487A (cg-RX-API-DMAC7.html) 2018-09-20
KR102558501B1 (ko) 2023-07-21
EP3402532A1 (en) 2018-11-21
US20250333396A1 (en) 2025-10-30
US20230416236A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP7439023B2 (ja) 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
KR102956244B1 (ko) 캄프토테신 제약 조성물의 안정화
JP2018524382A (ja) キラルジアリール大環状分子及びその使用
US20210228567A1 (en) Stabilizing Camptothecin Pharmaceutical Compositions
WO2019073296A1 (en) LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF
CN121646480A (zh) 治疗p53基因突变或缺陷阴性癌症、肿瘤患者
WO2025011621A1 (zh) Polq抑制剂化合物和抗癌治疗剂或者放射疗法的组合
HK40065701A (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
HK40065701B (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
CN121969391A (zh) 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症
AU2023360058A1 (en) Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones.
EA039513B1 (ru) Ингибитор атаксии-телеангиэкстазии и rad3-родственного белка (atr) и содержащие его липосомные композиции
CN114773321B (zh) 一种苯并咪唑衍生物及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240407

Address after: California, USA

Applicant after: Celet Pharmaceuticals

Country or region after: U.S.A.

Address before: Massachusetts, USA

Applicant before: MERRIMACK PHARMACEUTICALS, Inc.

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: California, USA

Patentee after: Jazz Pharmaceutical Treatment Co.

Country or region after: U.S.A.

Address before: California, USA

Patentee before: Celet Pharmaceuticals

Country or region before: U.S.A.